



May 26, 2026

To,
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

COMPANY CODE : BAYERCROP
SCRIP CODE : 506285

Dear Sir / Madam,

Sub.: News Release - Audited Financial Results for the Financial Year ended on March 31, 2026.

We send herewith a copy of the News Release that is being issued by the Company today, in connection with the captioned subject.

You are requested to kindly take note of the same.

Thanking You.

Yours faithfully,

for **Bayer CropScience Limited**

Bharati Shetty
Company Secretary and Compliance Officer
(Membership No. ACS 24199)

Encl.: As above

Bayer CropScience Ltd.
CIN: L24210MH1958PLC011173

Registered and Corporate Office:
Bayer House
Central Avenue
Hiranandani Estate
Thane (West) – 400 607
Maharashtra, India

Tel : +91 22 2531 1234
Fax : +91 22 2545 5063
www.bayer.in
www.cropscience.bayer.com

RESTRICTED



Bayer CropScience Limited
Communications
Bayer House, Hiranandani Estate
Thane (West) - 400607
Maharashtra, India
www.bayer.in

News Release

Financial Results for FY 2025-26

Bayer CropScience Limited Reports Q4 & Annual Results

- **FY 2025-26:** Revenue from Operations of ₹56,750 million and Profit Before Tax of ₹8,549 million
- **Q4 2025-26:** Revenue from Operations of ₹11,008 million and Profit Before Tax of ₹2,064 million

Mumbai, May 26, 2026: Bayer CropScience Limited (BSE: 506285) on Tuesday announced its results for the financial year (FY) and quarter ended March 31, 2026.

In FY 2025-26, the Company's Revenue from Operations increased to ₹56,750 million, compared to ₹54,734 million in the previous year. Profit Before Tax stood at ₹8,549 million, compared to ₹7,074 million in the previous year.

In Q4 of FY 2025-26, the Company registered Revenue from Operations of ₹11,008 million, compared to ₹10,464 million in the corresponding quarter of the previous year. Profit Before Tax for the quarter stood at ₹2,064 million, compared to ₹1,679 million in the corresponding quarter of the previous year.

Commenting on the quarterly results, Simon Wiebusch, Vice Chairman & Managing Director and CEO, BCSL said, "In Q4, we delivered a resilient performance, with revenue growing ~5%, reflecting the underlying strength of our business in a challenging environment, even as growth moderated versus our ambitions. While corn saw a softer season, our diversified portfolio sustained momentum.

Our full-year performance remained measured, shaped by Kharif disruptions and a deliberate focus on disciplined channel management and long-term value creation over short-term volume acceleration. We remain well-positioned to drive sustainable, quality-led growth going forward."

Speaking on the FY results, Vinit Jindal, Executive Director and Chief Financial Officer, BCSL, said, "Profit After Tax grew by 21% for the full year. Amidst external challenges, the Company maintained financial stability through disciplined cost and cash flow management. The balance sheet remains strong providing flexibility to support operations and strategic priorities. We continue to focus on driving profitable growth and maintaining balance-sheet resilience."

The Board of Directors has recommended a final dividend payment of ₹60/- per equity share of ₹10/- each for the financial year ended March 31, 2026, subject to shareholders' approval.

-END-

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality

throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Media Contact:

Snigdha Vishal

Communications, Bayer CropScience Limited

Email: snigdha.vishal@bayer.com

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.